OSR Health (OSRHW) Long-Term Investments (2023 - 2024)
OSR Health (OSRHW) posted Long-Term Investments of $1.8 million for Q4 2024, down 91.15% sequentially from $20.9 million in Q3 2024, and down 94.95% YoY from $36.6 million in Q1 2024.
OSR Health (OSRHW) Long-Term Investments (2023 - 2024) Analysis & Trends
OSR Health has reported Long-Term Investments for 2 years, with the latest figure at $1.8 million in Q4 2024.
- Quarterly Long-Term Investments fell 94.95% year-over-year to $1.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.8 million (down 94.95% YoY) and the FY2024 annual result came in at $1.8 million, down 94.95% from the prior year.
- Long-Term Investments fell to $1.8 million in Q4 2024 per OSRHW's latest filing, from $20.9 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $70.6 million in Q1 2023 and troughed at $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | - |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 372.10 Mn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | - |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 20.89 Mn |
| Jun 30, 2024 | 20.47 Mn |
| Mar 31, 2024 | 37.21 Mn |
| Dec 31, 2023 | 36.61 Mn |
| Sep 30, 2023 | 70.21 Mn |
| Jun 30, 2023 | 70.21 Mn |
| Mar 31, 2023 | 70.63 Mn |